ADC Therapeutics (ADCT) Stock Highlights

1.96 | -7.55%

2024-12-21 06:03:28

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The companys product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.

Statistics

Range Today

1.94 2.18

Volume Today 1.9M

Range 1 Year

1.18 6.04

Volume 1 Year 177.98M

Range 3 Year

0.36 22.52

Volume 3 Year 394.84M

Range 10 Year

0.36 56.59

Volume 10 Year 494.42M

Highlights

Market Capitalization 283.3M (small)

Floating Shares 77.09M

Current Price 1.96

Price To Earnings -1.2

Price To Revenue 6.43

Earnings Per Share -2.54

Payout Ratio 0%

Performance

Latest -7.55%

1 Month -6.67%

3 Months -39.13%

6 Months -26.32%

1 Year +35.17%

3 Years -89.99%

5 Years -93.47%

10 Years -93.47%

Benchmarks

Market Capitalization

180 / 368

Gross Profits

71 / 278

Total Revenue

82 / 300

Total Rank

7 / 368

Free Cashflow

294 / 352

Performance 5 years

295 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.